Abstract
Background: Previous dupilumab clinical trials have demonstrated efficacy with an acceptable safety profile in patients with moderate-to-severe atopic dermatitis (AD). Here we present an analysis of prior medication usage in patients initiating treatment with dupilumab enrolled in the GLOBOSTAD registry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
